Keyphrases
Tumor
78%
COVID-19
51%
Adverse Events
50%
Gemcitabine
44%
Overall Survival
41%
Pancreatic Cancer
35%
Klebsiella Pneumoniae (K. pneumoniae)
34%
Glioma
32%
Esophagectomy
31%
Radiosensitization
30%
COVID-19 Vaccine
30%
Durvalumab
29%
Stage III Non-small Cell Lung Cancer
29%
Circulating Tumor Cells
29%
Fitness Factor
28%
Checkpoint Kinase 1 (CHK1)
27%
Pancreatic Cancer Cells
26%
Non-small Cell Lung Cancer (NSCLC)
25%
Progression-free Survival
25%
High Risk
24%
Poor Prognosis
24%
Lung Adenocarcinoma
24%
Immunohistochemistry
23%
Vaccine Adverse Event Reporting System (VAERS)
23%
Hospitalized Patients
22%
Confidence Interval
22%
In Cancer
22%
Homologous Recombination Repair
22%
Effector T Cells
21%
11-oxygenated Androgens
21%
Esophageal Cancer
21%
Targeted Therapy
21%
Enhancer of Zeste Homolog 2 (EZH2)
20%
Inflammation
20%
Programmed Death-ligand 1 (PD-L1)
20%
Phase II Study
20%
T Cells
19%
Vaccine Adverse Events
19%
Survival Analysis
19%
Excision
19%
AZD7762
19%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
18%
Tumor Immunity
18%
Pathologist
17%
Myeloid-derived Suppressor Cells
17%
21-Hydroxylase Deficiency (21OHD)
17%
Primary Aldosteronism
17%
Survival Endpoint
17%
Simulation Study
17%
Comorbidity
17%
Medicine and Dentistry
Neoplasm
100%
Biological Marker
65%
COVID-19
48%
Ganglioglioma
45%
Esophagectomy
43%
Non Small Cell Lung Cancer
42%
Malignant Neoplasm
40%
Diseases
39%
Overall Survival
37%
Pancreas Cancer
34%
Adverse Event
33%
Melanoma
28%
Immunotherapy
27%
Gemcitabine
26%
Biopsy Technique
25%
Circulating Tumor Cell
25%
Cancer Cell
24%
Recurrent Disease
23%
Diagnosis
23%
Immunohistochemistry
21%
Esophageal Cancer
21%
Breast Carcinoma
20%
Lung Cancer
20%
Chemotherapy
20%
Androgen
19%
Radiosensitization
18%
Sensitization
18%
COVID-19 Vaccine
18%
Tetracosactide
18%
Immunity
18%
Comorbidity
18%
Progression Free Survival
17%
Pathologist
17%
Steroid 21 Monooxygenase Deficiency
17%
Checkpoint Kinase 1
17%
Primary Hyperaldosteronism
17%
5 (3 Fluorophenyl) N (3 Piperidinyl) 3 Ureido 2 Thiophenecarboxamide
16%
Thorax Surgery
16%
Progesterone Receptor
16%
Estrogen Receptor
16%
Surgery
16%
Chemoradiotherapy
16%
Hydrocortisone
15%
T Cell
15%
Urokinase Receptor
15%
Homologous Recombination
15%
Recombination Repair
15%
Quality of Life
14%
Mastectomy
14%
Pediatrics
13%